Showing promise in the landscape of obesity management, retatrutide presents a distinct method. Beyond many available medications, retatrutide functions as a twin agonist, simultaneously targeting both GLP-like peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) receptors. This dual stimulation fosters multiple helpful effects,